Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous PSCA-CAR-T cells
- Development stage
- Unknown
- Lead developer
- Hebei HOFOY Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous PSCA-CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy targeting prostate stem cell antigen (PSCA), a cell-surface glycoprotein overexpressed in prostate cancers, particularly castration-resistant prostate cancer (CRPC). Developed by Hebei General Hospital in collaboration with Hebei Medical University and Hebei HOFOY Biotech, these CAR-T cells are engineered using a non-viral minicircle DNA (mcDNA) platform rather than traditional viral vectors. This non-viral approach aims to improve safety, reduce manufacturing costs, and avoid insertional mutagenesis. The therapeutic candidate is being evaluated in a Phase 1/2 clinical trial in China for the treatment of patients with castration-resistant prostate cancer.
- Other names
- PSCA-CAR-T cellsautologous PSCA-targeted CAR-T cellsmcDNA-PSCA-CAR T cellsmcDNA-PSCA-CAR-T cells
02
Targets
PSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on autologous PSCA-CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous PSCA-CAR-T cells.